A case of squamous cell lung cancer treated with anamorelin in combination with a multidisciplinary collaborative approach for treating cancer cachexia

Yuri Oshima; Hiroyuki Matsuura; Yusuke Sakurai; Kaho Hirai; Eriko Tani; Naoki Yoshimoto; Kenichi Minami; Fumio Yamasaki; Mayu Nishime; Tomonori Hirashima

doi:10.1016/j.rmcr.2022.101609

A case of squamous cell lung cancer treated with anamorelin in combination with a multidisciplinary collaborative approach for treating cancer cachexia

Respir Med Case Rep. 2022 Feb 17:36:101609. doi: 10.1016/j.rmcr.2022.101609. eCollection 2022.

Authors

Affiliations

¹ Department of Respiratory Medicine, Ishikiriseiki Hospital, Osaka, Japan.
² Division of Rehabilitation, Ishikiriseiki Hospital, Osaka, Japan.
³ Division of Nutrition Management, Ishikiriseiki Hospital, Osaka, Japan.
⁴ Department of Thoracic Oncology, Ishikiriseiki Hospital, Osaka, Japan.

Abstract

Anamorelin (ANA) is approved for treating cancer cachexia (CCX) in Japan. We report the case of a 69-year-old man with stage IVB squamous cell lung cancer complicated by CCX, having a 13.6% weight loss in 6 months. After chemotherapy was initiated, his weight was further reduced. Therefore, we started ANA combined with a treatment approach by a multidisciplinary collaboration, including nutritionists and physical therapists. After initiation of ANA, the body weight, appetite, psoas muscle index, and physical functions rapidly improved during chemotherapy. ANA administration combined with a multidisciplinary collaboration approach can be an effective supportive therapy against CCX during chemotherapy.

Keywords: ANA, anamorelin; Anamorelin; BMI, body mass index; BW, body weight; BWL, body weight loss; CCX, cancer cachexia; CT, computed tomography; Cancer cachexia; LBM, lean body mass; Lung cancer; Multidisciplinary collaboration; NSCLC, non-small cell lung cancer; PMI, psoas muscle index.

Publication types

Case Reports